Charles Schwab Investment Management Inc Solid Biosciences Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.43 - $1.24 $54,354 - $156,742	-126,405 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$0.74 - $1.79 $18,153 - $43,912	-24,532 Reduced 16.25%	126,405 $152,000
Q2 2021 Aug 16, 2021	BUY	$3.49 - $5.51 $276,596 - $436,689	79,254 Added 110.56%	150,937 $553,000
Q1 2021 May 17, 2021	BUY	$5.37 - $10.72 $69,466 - $138,673	12,936 Added 22.02%	71,683 $397,000
Q4 2020 Feb 16, 2021	BUY	$3.08 - $7.79 $16,853 - $42,626	5,472 Added 10.27%	58,747 $446,000
Q3 2020 Nov 13, 2020	SELL	$2.02 - $3.08 $110,156 - $167,961	-54,533 Reduced 50.58%	53,275 $109,000
Q2 2020 Aug 14, 2020	BUY	$2.1 - $3.42 $39,116 - $63,704	18,627 Added 20.89%	107,808 $316,000
Q1 2020 May 15, 2020	BUY	$2.31 - $4.43 $2,940 - $5,639	1,273 Added 1.45%	89,181 $214,000
Q4 2019 Feb 07, 2020	SELL	$2.82 - $12.9 $16,420 - $75,116	-5,823 Reduced 6.21%	87,908 $392,000
Q3 2019 Nov 08, 2019	BUY	$4.33 - $11.64 $25,495 - $68,536	5,888 Added 6.7%	93,731 $970,000
Q2 2019 Aug 09, 2019	BUY	$4.6 - $10.13 $106,342 - $234,185	23,118 Added 35.72%	87,843 $506,000
Q1 2019 May 14, 2019	SELL	$7.19 - $32.37 $52,314 - $235,524	-7,276 Reduced 10.11%	64,725 $596,000
Q4 2018 Feb 14, 2019	SELL	$21.32 - $46.34 $40,699 - $88,463	-1,909 Reduced 2.58%	72,001 $1.93 Million
Q3 2018 Nov 13, 2018	BUY	$36.35 - $51.7 $1.3 Million - $1.86 Million	35,899 Added 94.44%	73,910 $3.49 Million
Q2 2018 Aug 08, 2018	BUY	$7.33 - $43.15 $19,483 - $114,692	2,658 Added 7.52%	38,011 $1.36 Million
Q1 2018 May 07, 2018	BUY	$7.19 - $33.17 $254,188 - $1.17 Million	35,353 New	35,353 $266,000

Others Institutions Holding SLDB

# of Institutions

Shares Held

Call Options Held

Put Options Held

View Full List

About Solid Biosciences Inc.

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $28.2M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

More about SLDB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account